T. Jerzy, Guzman Andrea, Ly Adama, Quintero Gabriela, Castillo Tatiana, Rojas Carolina, M. Jefferson, Penagos Pedro, S. Alexander, Lone You-Chun, O. S. Herve, Gutierrez-Coronado Oscar, Bierwagen Maciej, Rojas Carlos, Kasprzak Heliodor, P. Tadeusz, Ayala Adis, X. YueXin, P. Edwin, Santander Ricardo, A. Alvaro, A. Jaime, E. Luis, D. A. Donald, Briceno Ignacio, Trojan Annabelle
{"title":"In vitro Technical Aspects of Anti-Gene IGF-I Vaccines against Glioma","authors":"T. Jerzy, Guzman Andrea, Ly Adama, Quintero Gabriela, Castillo Tatiana, Rojas Carolina, M. Jefferson, Penagos Pedro, S. Alexander, Lone You-Chun, O. S. Herve, Gutierrez-Coronado Oscar, Bierwagen Maciej, Rojas Carlos, Kasprzak Heliodor, P. Tadeusz, Ayala Adis, X. YueXin, P. Edwin, Santander Ricardo, A. Alvaro, A. Jaime, E. Luis, D. A. Donald, Briceno Ignacio, Trojan Annabelle","doi":"10.36959/584/444","DOIUrl":null,"url":null,"abstract":"Research on glioblastoma has demonstrated a significant increase in IGF-I gene expression in this brain tumor. After suppression of IGF-I expression using anti-gene IGF-I technologies, glioma cells become immunogenic, expressing MHC-I. While injected in vivo, they induce an immune response mediated by T-CD8 lymphocytes. These cells, applied as autologous anti-cancer vaccines have increased the median survival of glioblastoma patients up to 18 months, but often up to two-three years. These differences in clinical results could be explained by variability in vaccine preparation standards.","PeriodicalId":92909,"journal":{"name":"Insights of biomedical research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Insights of biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36959/584/444","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Research on glioblastoma has demonstrated a significant increase in IGF-I gene expression in this brain tumor. After suppression of IGF-I expression using anti-gene IGF-I technologies, glioma cells become immunogenic, expressing MHC-I. While injected in vivo, they induce an immune response mediated by T-CD8 lymphocytes. These cells, applied as autologous anti-cancer vaccines have increased the median survival of glioblastoma patients up to 18 months, but often up to two-three years. These differences in clinical results could be explained by variability in vaccine preparation standards.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
